tiprankstipranks
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
Holding IKT?
Track your performance easily

Inhibikase Therapeutics (IKT) Cash flow

163 Followers

Inhibikase Therapeutics Cash Flow

IKT's free cash flow for Q3 2024 was $-4.88M. For the 2024 fiscal year, IKT's free cash flow was decreased by $-504.92K and operating cash flow was $-4.88M. See a summary of the company’s cash flow.
Cash Flow
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Operating Cash Flow
$ -17.91M$ -18.09M$ -17.35M$ -14.30M$ -1.13M$ -338.29K
Investing Cash Flow
$ 18.82M$ 11.66M$ -16.01M--$ 0.00
Financing Cash Flow
$ 3.79M$ 8.41M$ -204.77K$ 41.09M$ 15.06M$ -22.81K
Cash Flow From Discontinued Operation
------
Other Cash Adjustment Inside Changein Cash
------
End Cash Position
$ 21.21M$ 9.17M$ 7.19M$ 40.75M$ 13.95M$ 18.46K
Income Tax Paid Supplemental Data
------
Interest Paid Supplemental Data
--$ 973.00$ 1.15K$ 6.25K$ 9.15K
Issuance Of Capital Stock
$ 3.79M$ 8.54M-$ 41.14M$ 14.79M$ 0.00
Issuance Of Debt
--$ -248.91K$ -42.53K$ 272.80K$ 0.00
Repayment Of Debt
--$ -248.91K$ -42.53K$ 0.00$ -22.81K
Free Cash Flow
$ -17.91M$ -18.10M$ -17.59M$ -14.30M$ -1.13M$ -338.29K
Domestic Sales
------
Foreign Sales
------
Currency in USD

Inhibikase Therapeutics Cash Flow

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis